Compare Bristol-Myers Squibb Co (BMY) vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 (USOI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 — how do they compare? Bristol-Myers Squibb Co trades at $63.67 (market cap $129.94B), while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 trades at $45.6. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 nearer its low. Which is the better fit depends on your goals.
| BMY | USOI | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $65.89 | $61.17 |
52-Week Low | $42.60 | $42.27 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
USOI (Credit Suisse X-Links Crude Oil Shares Covered Call ETN) trades at $45.63, down 0.15% on the day. Technical indicators show a bullish bias with moving averages and oscillators favoring buys, though RSI levels suggest potential overbought conditions. The ETN's unique structure provides exposure to crude oil with covered call strategies, generating high yields but with complex risk profiles.
The outlook remains tied to oil price volatility and covered call performance. High yield potential attracts income investors, but structural complexity and oil market dependence pose significant risks. Recent media coverage highlights USOI's unconventional nature compared to traditional ETFs or bonds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037
USOI is an Exchange-Traded Note (ETN) issued by UBS that provides exposure to a covered call strategy on the United States Oil Fund (USO). It aims to generate high monthly income by capturing option premiums from the hypothetical sale of out-of-the-money call options on oil shares, offering a way to profit from crude oil's volatility even in a flat or range-bound market.
Read more on USOI →
